Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.

Autor: Hanson, Amanda¹ (AUTHOR), Elpek, Kutlu¹ (AUTHOR), Duong, Ellen¹ (AUTHOR), Shallberg, Lindsey¹ (AUTHOR), Fan, Martin¹ (AUTHOR), Johnson, Calvin¹ (AUTHOR), Wallace, Matthew² (AUTHOR), Mabry, George R.² (AUTHOR), Sazinsky, Stephen² (AUTHOR), Pepper, Lauren² (AUTHOR), Shu, Chengyi J.³ (AUTHOR), Sathyanarayanan, Sriram³ (AUTHOR), Zuerndorfer, Sarah² (AUTHOR), Simpson, Tyler¹ (AUTHOR), Gostissa, Monica⁴ (AUTHOR), Briskin, Michael⁵ (AUTHOR), Law, Deborah⁵ (AUTHOR), Michaelson, Jennifer¹ (AUTHOR), Harvey, Christopher J.¹ (AUTHOR) charvey@jouncetx.com

Publikováno v: PLoS ONE. 9/24/2020, Vol. 15 Issue 9, p1-21. 21p.

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.

Autor: Mazzone, Roberta^1,2, Zwergel, Clemens¹, Mai, Antonello^1,3 antonello.mai@uniroma1.it, Valente, Sergio¹ Sergio.valente@uniroma1.it

Publikováno v: Clinical Epigenetics. 5/30/2017, Vol. 9, p1-15. 15p.

Innate and adaptive immune responses of snatchfarrowed porcine-colostrum-deprived pigs to Mycoplasma hyopneumoniae vaccination.

Autor: Yanyun Huang^1,2 Yanyun.Huang@usask.ca, Ladinig, Andrea¹ Andrea.Ladinig@usask.ca, Ashley, Carolyn¹ Carolyn.Ashley@usask.ca, Haines, Deborah M.³ Debbie.Haines@usask.ca, Harding, John C. S.¹ John.Harding@usask.ca

Publikováno v: BMC Veterinary Research. 10/1/2014, Vol. 10 Issue 1, p1-14. 14p.

Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.

Autor: Nüssing, Simone, Trapani, Joseph A., Parish, Ian A.

Publikováno v: Frontiers in Immunology; 9/23/2020, Vol. 11, pN.PAG-N.PAG, 16p